PLCG2 and B-cell chronic lymphocytic leukemia: Furthermore, PLCγ2 mutations R665W and L845F in Ibrutinib-resistant CLL were shown to be hypersensitive to the Rho GTPase, Rac2 protein in vitro, which may suggest Rac2 as a potential target of refractory disease (135).